This preventive drug could be a 'game changer' in ending the HIV …
WEB3 days ago · Lenacapavir’s cost as HIV treatment in the United States in 2023 was $42,250 per new patient per year. Oral PrEP options, on the other hand, can cost less than $4 a month. Given the drug’s potential, Tremblay says that it is critical for access to be as widespread as possible. “The infrastructure needs to be in place to reach at-risk ...
An injectable HIV-prevention drug is highly effective - NBC News
WEBSep 12, 2024 · Thrilled over the news Thursday that lenacapavir was 89% more effective at preventing HIV than daily oral preventive medication among gay, bisexual and transgender people, plus previous...
Twice-a-year injection reduced risk of HIV infection by 96%, drug …
WEBSep 12, 2024 · In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from drugmaker Gilead...
Gilead’s twice-yearly lenacapavir outperforms Truvada in men
WEBThu, Sep 12, 2024, 12:33 PM 2 min read. Gilead has unveiled positive topline results from an interim analysis of its Phase III PURPOSE 2 trial showing that its twice-yearly HIV drug lenacapavir ...
Twice-yearly shot proves successful at preventing HIV infection …
WEBJul 24, 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
Lenacapavir Reduces HIV Infections by 96%, Demonstrates …
WEBSep 12, 2024 · The results demonstrated superiority of twice-yearly lenacapavir over bHIV (incidence 2.37 per 100 person-years), with 96% relative risk reduction (incidence rate ratio 0.04, p<0.0001). 1. There were 9 incident cases among 1,087 individuals in the Truvada group (incidence 0.93 per 100 person-years). Twice-yearly lenacapavir was 89% more ...
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBJun 20, 2024 · The results demonstrated superiority of twice-yearly lenacapavir over bHIV (primary endpoint, incidence 2.41 per 100 person-years) and superiority of twice-yearly lenacapavir over once-daily Truvada (secondary endpoint), with …
New HIV drug can only offer hope of ending AIDS if all have …
WEBGENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.
Full Efficacy and Safety Results for Gilead Investigational Twice ...
WEBJul 24, 2024 · The new data provide details on the efficacy, safety and tolerability of twice-yearly lenacapavir injections; drug adherence among trial participants, including poor levels of adherence to daily oral pre-exposure prophylaxis (PrEP) and high levels of adherence to lenacapavir; and demographic and behavioral characteristics of trial participants ...
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class ...
WEBDec 22, 2022 · Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV. – Sunlenca is the First and Only Approved Capsid Inhibitor-Based HIV Treatment Option –. – New Drug Application Approval Based on High Rates of Sustained Virologic Suppression in …
Skip to content